Ser278
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser278  -  ataxin-7L3 (human)

Site Information
RLQWDGSsDLsPSDS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4272586

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 )
Disease tissue studied:
leukemia ( 3 ) , acute myelogenous leukemia ( 3 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:
H2077 (pulmonary) ( 1 ) , H322M (pulmonary) ( 1 ) , HCC366 (pulmonary) ( 1 ) , HCC78 (pulmonary) ( 1 ) , Jurkat (T lymphocyte) ( 4 ) , KG-1 (myeloid) ( 3 ) , LOU-NH91 (squamous) ( 1 ) , NCI-H460 (pulmonary) ( 1 )

References 

1

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

2

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

3

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

4

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info